Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 100 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials).,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.

Malta - Inggeris - Malta Medicines Authority

generics uk limited - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - salmeterol xinafoate 25 µg; fluticasone propionate 125 µg - drugs for obstructive airway diseases

Malta - Inggeris - Malta Medicines Authority

generics uk limited - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - salmeterol xinafoate 25 µg; fluticasone propionate 250 µg - drugs for obstructive airway diseases

Malta - Inggeris - Malta Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - salmeterol, fluticasone propionate - pressurised inhalation, suspension - salmeterol 25 µg fluticasone propionate 50 µg - drugs for obstructive airway diseases

Malta - Inggeris - Malta Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - salmeterol, fluticasone propionate - pressurised inhalation, suspension - salmeterol 25 µg fluticasone propionate 125 µg - drugs for obstructive airway diseases

Malta - Inggeris - Malta Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - salmeterol, fluticasone propionate - pressurised inhalation, suspension - salmeterol 25 µg fluticasone propionate 250 µg - drugs for obstructive airway diseases

Malta - Inggeris - Malta Medicines Authority

glenmark pharmaceuticals nordic ab propellergatan 2 se-211 15 malmö, sweden - salmeterol, fluticasone propionate - inhalation powder, pre-dispensed - salmeterol 50 µg fluticasone propionate 500 µg - drugs for obstructive airway diseases

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - asthma - drugs for obstructive airway diseases, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.